Cluster headaches are classified as a trigeminal autonomic cephalgia — a group of primary headache disorders characterised by unilateral, periorbital pain of extraordinary intensity. Patients and clinicians alike describe the pain as among the most severe a human being can experience, often referred to informally as suicide headaches. Conventional treatment options are limited, and a significant minority of patients do not achieve adequate control with licensed therapies. Medical cannabis is increasingly considered as an adjunctive option for refractory cases.

What Are Cluster Headaches?

Cluster headaches occur in discrete episodes lasting 15 minutes to three hours, recurring multiple times per day during a cluster period that may last weeks or months, followed by remission. Episodic cluster headache involves identifiable remission periods; chronic cluster headache is defined by attacks persisting for more than a year without remission, or with remissions shorter than three months. Associated features include ipsilateral lacrimation, nasal congestion, ptosis, and agitation that distinguishes the condition clearly from migraine.

Trigeminal autonomic cephalgias as a group include SUNCT (short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing) and paroxysmal hemicrania in addition to cluster headache. Each has distinct treatment profiles, and what applies to cluster headache does not automatically extend to other conditions in the group.

Why Conventional Treatments Are Insufficient for Many Patients

First-line acute treatment for cluster headache is high-flow oxygen therapy (100% oxygen at 12 to 15 litres per minute via non-rebreather mask) and subcutaneous sumatriptan. Both are effective in a substantial proportion of patients but have significant limitations: home oxygen requires prescribing and supply logistics that many patients find difficult to manage; sumatriptan is contraindicated in patients with cardiovascular disease; and neither prevents attacks. Preventive options include verapamil, lithium, and short-course oral corticosteroids for transitional use. Response rates are partial, side effect profiles are material, and a clinically meaningful subgroup of patients remains refractory despite trials of multiple agents.

For chronic cluster headache in particular, treatment-resistant presentations are common, and patients may spend years cycling through agents with inadequate relief. This is the population for whom cannabis-based medicines are most likely to be considered by a prescribing specialist.

Evidence for Cannabis-Based Medicines in Cluster Headache

The evidence base for cannabis in cluster headache is substantially smaller than for conditions such as neuropathic pain or spasticity. There are no large randomised controlled trials. However, there is a body of case report, retrospective survey, and observational data suggesting that some patients with cluster headache experience meaningful reduction in attack frequency and severity with cannabinoid use. A survey of cluster headache patients published in 2019 reported that a subset described cannabis as more effective than conventional treatments, though the limitations of self-reported survey data must be acknowledged.

Mechanistically, the trigeminal nucleus caudalis and the trigeminovascular system express cannabinoid receptors (CB1 and CB2), providing a plausible biological basis for cannabinoid effects on cluster headache pathophysiology. THC and CBD both modulate nociceptive signalling, and endocannabinoid system dysfunction has been proposed as a contributing factor in primary headache disorders including cluster headache.

Psilocybin has attracted attention in cluster headache research and is sometimes discussed alongside cannabis, but these are separate substances with distinct legal and clinical profiles. Cannabis prescribing for cluster headache sits within the UK unlicensed specialist prescribing framework and does not involve other substances.

What Cannabis-Based Medicines Are Used?

UK specialists prescribing for cluster headache typically use oil-based formulations containing THC and CBD in combination, or CBD-dominant preparations. Vaporised cannabis may be considered for acute attack management due to its faster onset, though this requires careful discussion given the respiratory considerations and the practical challenges of using vaporised medicine during a cluster attack, which typically involves severe agitation. Most prescribing in the UK for headache disorders uses sublingually administered oils as a preventive strategy rather than acute rescue therapy.

Dosing is highly individualised and will be titrated by the prescribing specialist. Patients should not expect a rapid and dramatic transformation. Clinical response assessment typically requires at least six to eight weeks of consistent dosing at a therapeutic level before meaningful evaluation is possible.

Accessing a Prescription for Cluster Headache in the UK

Cluster headache is not on any official NICE or NHS approved-indications list for cannabis-based medicines. Prescribing occurs under the unlicensed specialist prescribing framework, which means a consultant or specialist registered with the GMC can prescribe where they consider it clinically appropriate, having documented that the patient has tried and failed conventional options.

Patients seeking a cannabis prescription for cluster headache should expect to provide documentation of their diagnosis — ideally from a neurologist or headache specialist — and a treatment history demonstrating that licensed options have been trialled without adequate response. Not all private cannabis clinics accept cluster headache referrals; clinics with neurological experience are the appropriate starting point. See the UK medical cannabis clinics section for an overview of prescribers.

Realistic Expectations

Cannabis-based medicines are not a cure for cluster headache and are not appropriate as a first-line treatment. Patients with cluster headache who have not yet trialled high-flow oxygen, sumatriptan, and preventive agents such as verapamil should pursue those pathways first, ideally via a neurologist or GP with headache experience. The role of cannabis in this condition is as an adjunctive option for patients who have exhausted or are unable to tolerate conventional treatments, and where a specialist considers the benefit-risk balance to be favourable on an individual basis.

For a full overview of the prescription process, see how to get a medical cannabis prescription in the UK.

Frequently Asked Questions — Medical Cannabis for Cluster Headaches UK

Is cluster headache a qualifying condition for medical cannabis in the UK?

There is no official NHS approved-indications list that includes cluster headache specifically. A GMC-registered specialist can prescribe under the unlicensed specialist prescribing framework if clinically appropriate, typically after conventional treatments have been tried without adequate response. Eligibility is assessed individually.

Will I need a neurologist referral to get a prescription?

A confirmed diagnosis — ideally documented by a neurologist or a GP with specialist headache knowledge — will be required. Some private cannabis clinics will accept a GP letter confirming the diagnosis and treatment history. A full prior treatment history must be provided demonstrating that licensed options have been trialled.

Can cannabis stop a cluster headache attack when it is happening?

Most cannabis prescribing in the UK for cluster headache is preventive — using oils taken on a regular schedule to reduce attack frequency and severity. Vaporised cannabis has a faster onset and has been used by some patients for acute attacks, but managing an acute cluster headache attack requires rapid-acting treatments such as oxygen or subcutaneous sumatriptan that have a more robust evidence base for acute use.

Are cluster headaches and migraines treated in the same way with cannabis?

They are distinct conditions with different underlying mechanisms and different treatment profiles. Some overlap exists in that both involve the trigeminal system, and some patients with either condition report benefit from cannabis-based medicines. However, a prescriber will assess them separately, and treatment decisions for one condition do not automatically apply to the other.

How long does it take to know whether cannabis-based medicine is helping?

A meaningful assessment typically requires six to eight weeks of consistently titrated dosing. Because cluster headache occurs in discrete periods, evaluation may also need to span an entire cluster cycle. Your prescribing specialist will set clear review milestones to assess response objectively.